Mifepristone

• 

  Subject Areas on Research

  • 16 alpha-substituted analogs of the antiprogestin RU486 induce a unique conformation in the human progesterone receptor resulting in mixed agonist activity. 
  • Cardiac arrest and resuscitation activates the hypothalamic-pituitary-adrenal axis and results in severe immunosuppression. 
  • Creatine kinase activity as an indicator of unopposed estrogen action in the mouse uterus associated with anti-progesterone treatment. 
  • Definition of the critical cellular components which distinguish between hormone and antihormone activated progesterone receptor. 
  • Effects of D-ring substituents on antiprogestational (antagonist) and progestational (agonist) activity of 11 beta-aryl steroids. 
  • Effects of progesterone and estradiol sex hormones on the release of microparticles by RAW 264.7 macrophages stimulated by Poly(I:C). 
  • Endocrine therapy in metastatic breast cancer. 
  • Endurance exercise training increases adipose tissue glucocorticoid exposure: adaptations that facilitate lipolysis. 
  • Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. 
  • Identification and characterization of novel estrogen receptor-beta-sparing antiprogestins. 
  • Identification of a negative regulatory function for steroid receptors. 
  • Insulin inhibits dexamethasone effect on angiotensinogen gene expression and induction of hypertrophy in rat kidney proximal tubular cells in high glucose. 
  • Ligand-specific dynamics of the androgen receptor at its response element in living cells. 
  • Mechanisms controlling agonist and antagonist potential of selective progesterone receptor modulators (SPRMs). 
  • Mechanisms of progesterone receptor inhibition of inflammatory responses in cellular models of breast cancer. 
  • Mifepristone (RU 486) for Alzheimer's disease. 
  • Mifepristone (RU-486®) as a Schedule IV Controlled Drug-Implications for a Misleading Drug Policy on Women's Health Care. 
  • Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. 
  • Peptide antagonists of the human estrogen receptor. 
  • RU486 blocks the anti-inflammatory effects of exercise in a murine model of allergen-induced pulmonary inflammation. 
  • RU486 exerts antiestrogenic activities through a novel progesterone receptor A form-mediated mechanism. 
  • RU486 in depression. 
  • Synergistic effect of dexamethasone and isoproterenol on the expression of angiotensinogen in immortalized rat proximal tubular cells. 
  • The Novel Progesterone Receptor Antagonists RTI 3021-012 and RTI3021-022 Exhibit Complex Glucocorticoid Receptor Antagonist Activities: Implications for the Development of Dissociated Antiprogestins. 
  • The human progesterone receptor A-form functions as a transcriptional modulator of mineralocorticoid receptor transcriptional activity. 
  • The mechanism of RU486 antagonism is dependent on the conformation of the carboxy-terminal tail of the human progesterone receptor. 
  • The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. 
  • The opposing transcriptional activities of the two isoforms of the human progesterone receptor are due to differential cofactor binding. 
• 

  Keywords of People

  • McDonnell, Donald Patrick, Glaxo-Wellcome Distinguished Professor of Molecular Cancer Biology, in the School of Medicine, Pharmacology & Cancer Biology